News | October 14, 2013

Voices Against Brain Cancer Comments on Preservation of Cognitive Function After Radiotherapy

October 14, 2013 — Voices Against Brain Cancer (VBAC), an organization dedicated to brain cancer research and advocacy, discussed a study that looked into the preservation of cognitive function for brain cancer patients after radiotherapy treatments.

According to an October 7 article published by Drug Discovery & Development magazine titled “Drug Preserves Cognitive Function After WBRT for Brain Cancer,” researchers at Emory’s Nell Hodgson Woodruff School of Nursing and the Winship Cancer Institute conducted a study that highlighted positive outcomes “in long-term cognitive function due to the use of the cognitive drug Memantine.” The findings could be used to help brain cancer patients who undergo whole-brain radiotherapy (WBRT). Although it has been proven to be a therapeutic survival tool in the treatment of adults with brain tumors, it does have lingering negative effects in the long-term brain function and performance of those who undergo this treatment.

In the study, 508 eligible adult WBRT patients received placebo or memantine within three days of starting WBRT and for 24 weeks in “graduated doses.” The participants were then given a series of cognitive function tests and also underwent neurologic exams, history and physical exams, performance status and brain magnetic resonance imaging (MRIs) and computer tomography (CT) scans.

Deborah Watkins Bruner, Ph.D., R.N., professor, Nell Hodgson Woodruff School of Nursing and associate director of cancer outcomes, Winship Cancer Institute at Emory, was content with the preliminary results, which showed better cognitive function over time for those who took memantine.

“We specifically saw a delay in the time of cognitive decline and reductions in the rates of memory loss, executive function and processing-speed declines,” said Watkins-Bruner.

Michael Klipper, chairman, VBAC, said this finding will provide hope to the brain cancer community.

“Even though this study is still in its preliminary trial and some questions about the drug’s effectiveness do remain, this is an extremely positive step towards preventing cognitive dysfunction and bettering the lives of brain cancer patients,” said Klipper.

For more information: www.voicesagainstbraincancer.org, www.dddmag.com

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at